CD274 and ovarian cancer: Although novel therapeutic reagents, such as PARP inhibitors and anti-PD-1 and/or anti-PD-L1 antibodies, have been tested during these two decades, the five-year OS of ovarian cancer patients still just remains to 30 – 40 percent.